Multicentre testing of the EUCAST broth microdilution reference method for MIC determination on Mycobacterium tuberculosis
Autor(a) principal: | |
---|---|
Data de Publicação: | 2021 |
Outros Autores: | , , , , , , , , , , , , |
Tipo de documento: | Artigo |
Idioma: | eng |
Título da fonte: | Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
Texto Completo: | http://hdl.handle.net/10362/116505 |
Resumo: | Objectives: The first objective of the European Committee on Antimicrobial Susceptibility Testing (EUCAST) subcommittee for antimycobacterial susceptibility testing (AMST), launched in 2016, was to set a reference method for determining the MICs of antituberculous agents, since many protocols are used worldwide and a consensus one is needed for the determination of microbiological breakpoints. Methods: During 2017 and 2018, MIC determination protocols were evaluated prospectively in a multicentre study within the four AMST laboratories. MIC results were obtained for isoniazid, levofloxacin and amikacin on the reference strain Mycobacterium tuberculosis H37Rv ATCC 27294. Broth microdilution (BMD) in Middlebrook 7H9 and solid medium dilution (SMD) in Middlebrook 7H10 were performed using two inoculum concentrations. MICs were interpreted with regard to visual and 99% inhibition after 7, 14 or 21 days of incubation for BMD and 21 days for SMD. Results: Following the EUCAST reference protocol, intra- and inter-assay agreements were within ±1 MIC dilution for >95% of the observations for the three drugs in both methods. MIC values, presented as MIC mode (range) for BMD and SMD respectively, were: 0.03 (0.015–0.06) mg/L and 0.12 (0.06–0.25) mg/L for isoniazid, 0.25 mg/L (0.25–0.5) and 0.5 mg/L (0.12–0.5) for levofloxacin, and 0.5 mg/L (0.5–1.0) and 0.5 mg/L (0.5–1.0) for amikacin. Conclusions: Both SMD and BMD were reproducible and eligible as a reference method for MIC determination of the Mycobacterium tuberculosis complex (MTBC). BMD was finally selected as the EUCAST reference method. From now on it will be used to set epidemiological cut-off values and clinical breakpoints of new and old antituberculous agents. |
id |
RCAP_50a5ac3e6af5c6047bbbd54ff6bc2205 |
---|---|
oai_identifier_str |
oai:run.unl.pt:10362/116505 |
network_acronym_str |
RCAP |
network_name_str |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
repository_id_str |
7160 |
spelling |
Multicentre testing of the EUCAST broth microdilution reference method for MIC determination on Mycobacterium tuberculosisAmikacinBroth microdilutionEUCASTIsoniazidLevofloxacinMICReference methodTuberculosisMicrobiology (medical)Infectious DiseasesSDG 3 - Good Health and Well-beingSDG 9 - Industry, Innovation, and InfrastructureObjectives: The first objective of the European Committee on Antimicrobial Susceptibility Testing (EUCAST) subcommittee for antimycobacterial susceptibility testing (AMST), launched in 2016, was to set a reference method for determining the MICs of antituberculous agents, since many protocols are used worldwide and a consensus one is needed for the determination of microbiological breakpoints. Methods: During 2017 and 2018, MIC determination protocols were evaluated prospectively in a multicentre study within the four AMST laboratories. MIC results were obtained for isoniazid, levofloxacin and amikacin on the reference strain Mycobacterium tuberculosis H37Rv ATCC 27294. Broth microdilution (BMD) in Middlebrook 7H9 and solid medium dilution (SMD) in Middlebrook 7H10 were performed using two inoculum concentrations. MICs were interpreted with regard to visual and 99% inhibition after 7, 14 or 21 days of incubation for BMD and 21 days for SMD. Results: Following the EUCAST reference protocol, intra- and inter-assay agreements were within ±1 MIC dilution for >95% of the observations for the three drugs in both methods. MIC values, presented as MIC mode (range) for BMD and SMD respectively, were: 0.03 (0.015–0.06) mg/L and 0.12 (0.06–0.25) mg/L for isoniazid, 0.25 mg/L (0.25–0.5) and 0.5 mg/L (0.12–0.5) for levofloxacin, and 0.5 mg/L (0.5–1.0) and 0.5 mg/L (0.5–1.0) for amikacin. Conclusions: Both SMD and BMD were reproducible and eligible as a reference method for MIC determination of the Mycobacterium tuberculosis complex (MTBC). BMD was finally selected as the EUCAST reference method. From now on it will be used to set epidemiological cut-off values and clinical breakpoints of new and old antituberculous agents.TB, HIV and opportunistic diseases and pathogens (THOP)Global Health and Tropical Medicine (GHTM)Instituto de Higiene e Medicina Tropical (IHMT)RUNSchön, ThomasWerngren, JimMachado, DianaBorroni, EmanueleWijkander, MariaLina, GerardMouton, JohanMatuschek, ErikaKahlmeter, GunnarGiske, ChristianSantin, MiguelCirillo, Daniela MariaViveiros, MiguelCambau, Emmanuelle2021-04-30T22:43:25Z2021-022021-02-01T00:00:00Zinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/article4application/pdfhttp://hdl.handle.net/10362/116505eng1198-743XPURE: 26636287https://doi.org/10.1016/j.cmi.2020.10.019info:eu-repo/semantics/openAccessreponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãoinstacron:RCAAP2024-03-11T04:59:07Zoai:run.unl.pt:10362/116505Portal AgregadorONGhttps://www.rcaap.pt/oai/openaireopendoar:71602024-03-20T03:43:06.156920Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãofalse |
dc.title.none.fl_str_mv |
Multicentre testing of the EUCAST broth microdilution reference method for MIC determination on Mycobacterium tuberculosis |
title |
Multicentre testing of the EUCAST broth microdilution reference method for MIC determination on Mycobacterium tuberculosis |
spellingShingle |
Multicentre testing of the EUCAST broth microdilution reference method for MIC determination on Mycobacterium tuberculosis Schön, Thomas Amikacin Broth microdilution EUCAST Isoniazid Levofloxacin MIC Reference method Tuberculosis Microbiology (medical) Infectious Diseases SDG 3 - Good Health and Well-being SDG 9 - Industry, Innovation, and Infrastructure |
title_short |
Multicentre testing of the EUCAST broth microdilution reference method for MIC determination on Mycobacterium tuberculosis |
title_full |
Multicentre testing of the EUCAST broth microdilution reference method for MIC determination on Mycobacterium tuberculosis |
title_fullStr |
Multicentre testing of the EUCAST broth microdilution reference method for MIC determination on Mycobacterium tuberculosis |
title_full_unstemmed |
Multicentre testing of the EUCAST broth microdilution reference method for MIC determination on Mycobacterium tuberculosis |
title_sort |
Multicentre testing of the EUCAST broth microdilution reference method for MIC determination on Mycobacterium tuberculosis |
author |
Schön, Thomas |
author_facet |
Schön, Thomas Werngren, Jim Machado, Diana Borroni, Emanuele Wijkander, Maria Lina, Gerard Mouton, Johan Matuschek, Erika Kahlmeter, Gunnar Giske, Christian Santin, Miguel Cirillo, Daniela Maria Viveiros, Miguel Cambau, Emmanuelle |
author_role |
author |
author2 |
Werngren, Jim Machado, Diana Borroni, Emanuele Wijkander, Maria Lina, Gerard Mouton, Johan Matuschek, Erika Kahlmeter, Gunnar Giske, Christian Santin, Miguel Cirillo, Daniela Maria Viveiros, Miguel Cambau, Emmanuelle |
author2_role |
author author author author author author author author author author author author author |
dc.contributor.none.fl_str_mv |
TB, HIV and opportunistic diseases and pathogens (THOP) Global Health and Tropical Medicine (GHTM) Instituto de Higiene e Medicina Tropical (IHMT) RUN |
dc.contributor.author.fl_str_mv |
Schön, Thomas Werngren, Jim Machado, Diana Borroni, Emanuele Wijkander, Maria Lina, Gerard Mouton, Johan Matuschek, Erika Kahlmeter, Gunnar Giske, Christian Santin, Miguel Cirillo, Daniela Maria Viveiros, Miguel Cambau, Emmanuelle |
dc.subject.por.fl_str_mv |
Amikacin Broth microdilution EUCAST Isoniazid Levofloxacin MIC Reference method Tuberculosis Microbiology (medical) Infectious Diseases SDG 3 - Good Health and Well-being SDG 9 - Industry, Innovation, and Infrastructure |
topic |
Amikacin Broth microdilution EUCAST Isoniazid Levofloxacin MIC Reference method Tuberculosis Microbiology (medical) Infectious Diseases SDG 3 - Good Health and Well-being SDG 9 - Industry, Innovation, and Infrastructure |
description |
Objectives: The first objective of the European Committee on Antimicrobial Susceptibility Testing (EUCAST) subcommittee for antimycobacterial susceptibility testing (AMST), launched in 2016, was to set a reference method for determining the MICs of antituberculous agents, since many protocols are used worldwide and a consensus one is needed for the determination of microbiological breakpoints. Methods: During 2017 and 2018, MIC determination protocols were evaluated prospectively in a multicentre study within the four AMST laboratories. MIC results were obtained for isoniazid, levofloxacin and amikacin on the reference strain Mycobacterium tuberculosis H37Rv ATCC 27294. Broth microdilution (BMD) in Middlebrook 7H9 and solid medium dilution (SMD) in Middlebrook 7H10 were performed using two inoculum concentrations. MICs were interpreted with regard to visual and 99% inhibition after 7, 14 or 21 days of incubation for BMD and 21 days for SMD. Results: Following the EUCAST reference protocol, intra- and inter-assay agreements were within ±1 MIC dilution for >95% of the observations for the three drugs in both methods. MIC values, presented as MIC mode (range) for BMD and SMD respectively, were: 0.03 (0.015–0.06) mg/L and 0.12 (0.06–0.25) mg/L for isoniazid, 0.25 mg/L (0.25–0.5) and 0.5 mg/L (0.12–0.5) for levofloxacin, and 0.5 mg/L (0.5–1.0) and 0.5 mg/L (0.5–1.0) for amikacin. Conclusions: Both SMD and BMD were reproducible and eligible as a reference method for MIC determination of the Mycobacterium tuberculosis complex (MTBC). BMD was finally selected as the EUCAST reference method. From now on it will be used to set epidemiological cut-off values and clinical breakpoints of new and old antituberculous agents. |
publishDate |
2021 |
dc.date.none.fl_str_mv |
2021-04-30T22:43:25Z 2021-02 2021-02-01T00:00:00Z |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
http://hdl.handle.net/10362/116505 |
url |
http://hdl.handle.net/10362/116505 |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.relation.none.fl_str_mv |
1198-743X PURE: 26636287 https://doi.org/10.1016/j.cmi.2020.10.019 |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
4 application/pdf |
dc.source.none.fl_str_mv |
reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação instacron:RCAAP |
instname_str |
Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação |
instacron_str |
RCAAP |
institution |
RCAAP |
reponame_str |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
collection |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
repository.name.fl_str_mv |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação |
repository.mail.fl_str_mv |
|
_version_ |
1799138041313361920 |